Tumor formation in Smarca4 heterozygous mice occurs with long latency and low penetrance56,57, indicating that for treatment of SMARCA4-dependent cancers a therapeutic index for transient inhibition of SMARCA4 might exist without the risk of secondary malignancies. This evidence concerns the gene SMARCA4 and cancer.